 The orally active SYK inhibitor fostamatinib (R788) in the treatment of immune thrombocytopenia.The Syk inhibitor nilvadipine has been shown to regulate amyloid-β production and Tau phosphorylation and hence has been proposed as a treatment for Alzheimer's Disease and has entered phase III clinical trials.The role of Syk in epithelial malignancies is controversial.